Rheumatoid arthritis
Rheumatoid arthritis
复制标题
DOI：
10.1016/j.beha.2004.05.002
复制
发表时间：
2004-06-01
影响因子：
2.1
通讯作者：
Moore, JJ
中科院分区：
文献类型：
--
作者：
Bingham, SJ;Moore, JJ
造血干细胞移植（HSCT）目前正被研究作为对常规治疗（包括肿瘤坏死因子-a阻断）无反应的严重难治性类风湿关节炎患者的潜在治疗方法。欧洲血液和骨髓移植组织/自体血液和骨髓移植登记处对全球病例的初步研究和分析使这项技术取得了进展。HSCT在类风湿关节炎患者中耐受性良好，并且没有移植相关的死亡率。虽然造血干细胞移植不能治愈疾病，但对以前无效的治疗方法的改善反应经常被看到。然而，需要进一步的研究，并且这种手术仍然被认为只适用于那些没有合理治疗选择的患者。本文回顾了以往所有与类风湿关节炎HSCT相关的数据，概述了目前的立场，并讨论了未来的方案选择和研究。
Haematopoietic stem cell transplantation (HSCT) is now being investigated as a potential therapy for patients with severe refractory rheumatoid arthritis unresponsive to conventional therapies, including tumour necrosis factor-a blockade. Pilot studies and an analysis of worldwide cases included in the European Group for Blood and Marrow Transplartation/Autologous Blood and Marrow Transplant Registry registry have enabled the progression of the technique. HSCT is well tolerated in patients with rheumatoid arthritis, and there has been no transplant-related mortality. Although HSCT is not a cure, an improved response to previously ineffective therapies is often seen. Further research is, however, required, and this procedure is still considered appropriate only for those patients for whom there is no reasonable therapeutic alternative. This paper reviews all the previous data relating to HSCT in rheumatoid arthritis, outlines the current stand and discusses future protocol options and research.